Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis

This is a Phase 1, multicenter, dose-escalation, open-label study to assess safety, tolerability, preliminary activity, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 or high-risk myelofibrosis.

  • 7 views
  • 27 Oct, 2021
  • 5 locations
None
To Assess the Safety Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

myelofibrosis
ruxolitinib
  • 0 views
  • 05 Oct, 2021
  • 14 locations
None
  • 0 views
  • 30 Nov, 2021
  • 13 locations
None
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only treatment with proven curative potential for

cyclophosphamide
tacrolimus
graft versus host disease
hemolysis
fludarabine
  • 72 views
  • 07 Oct, 2021
  • 1 location
None
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

This phase II trial studies how well giving a JAK inhibitor before a donor stem cell transplant works in treating patients with myelofibrosis that developed without another condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop the growth of …

cyclophosphamide
abnormal cells
hemolysis
fludarabine
stem cell transplantation
  • 139 views
  • 11 Jul, 2021
  • 1 location
None
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF

  • 0 views
  • 28 Nov, 2021
  • 1 location
None
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF ET-MF) or Acute Myeloid Leukemia

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid leukemia (AML).

refractory acute myeloid leukemia (aml)
  • 0 views
  • 17 Jun, 2021
  • 3 locations
None
Combination Chemotherapy Total Body Irradiation and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

This pilot phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with secondary myelofibrosis

  • 31 views
  • 27 Aug, 2021
  • 2 locations
None
P1101 in Treating Patients With Myelofibrosis

This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of myelofibrosis.

platelet count
essential thrombocythemia
thrombocytosis
anemia
leukemia
  • 53 views
  • 18 Apr, 2021
  • 1 location
None
  • 0 views
  • 01 Apr, 2021
  • 2 locations